Join
Live feed
·
PRReleasevia Quantisnow
ImmunoGen Inc. logo

ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer

ByQuantisnow·Wall Street's wire, on your screen.
IMGN· ImmunoGen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMGN (ImmunoGen Inc.) and more on Quantisnow.